Novel Drug for Obesity, Diabetes, and Cardiovascular Protection Announced at International Cardiology Congress
A novel pharmaceutical treatment targeting obesity, diabetes, and offering comprehensive protection for the heart, kidneys, and liver, was unveiled at the International Congress for the Prevention of Cardiovascular Diseases and High Blood Pressure, held in Djerba from March 27-29, 2026. The medication is slated for availability in Tunisia within one month, but will require a prescription from a specialist physician.
Addressing a Significant Health Challenge in Tunisia
Dr. Leïla Obeid, head of the cardiology and vascular diseases department at the Hédi Chaker University Hospital in Sfax, highlighted the importance of this advancement given the prevalence of metabolic diseases in Tunisia. Currently, 30% of the Tunisian population suffers from hypertension, 30% from obesity, and 18% from diabetes ISCVDP.
Focus on Prevention and Early Detection
The congress emphasized the critical role of primary prevention and early detection of pre-diabetic and pre-hypertensive conditions. This proactive approach aims to curb the increasing incidence of cardiovascular diseases, which remain the leading cause of mortality in the country ISCVDP. The event featured conferences and practical workshops, bringing together Tunisian and European specialists in cardiology, endocrinology, and nephrology, alongside practicing physicians.
Collaborative Effort for Improved Healthcare
The congress was organized by the cardiology service of Sfax, in collaboration with the services of Médenine and Gabès, under the supervision of the Tunisian Ministry of Health and the Tunisian Society of Cardiology and Cardiovascular Surgery ISCVDP.
Global Cardiology Events in 2026
Several other significant cardiology events are scheduled for 2026, offering opportunities for continued learning and collaboration:
- 13th World Congress on Hypertension, Cardiology & Primary Health: May 21–22, 2026, Paris, France Cardiology Meeting
- 29th Annual International Congress on Cardiovascular Disease Prevention: May 30th to June 7th, Japan ISCVDP
- 13th International Conference on Hypertension and Cardiovascular Diseases: April 19-20, 2026, Rome, Italy Europe Annual Conferences
Looking Ahead
The introduction of this new treatment in Tunisia represents a significant step forward in the prevention and management of metabolic diseases. It offers hope for reducing cardiovascular risks and improving the overall health of the population. Continued research, collaboration, and a focus on preventative measures will be essential in addressing the global burden of cardiovascular disease.